Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas

Table 4 Multivariate survival analysis of S1PR1/pSTAT3 expression and clinicopathologic variables for overall survival in a total cohort of rituximab-treated DLBCL patients (N = 103)

Multivariate analysis with IPI, B symptoms, and S1PR1
Clinicopathologic variables	Category	Univariate analysis	Multivariate analysis
		P^*	P^*	HR [95% CI]
IPI	3-5 vs. 0-2	0.009	0.019	2.7 [1.2-6.2]
B symptoms	present vs. absent	0.014	0.180	1.7 [0.8-3.9]
S1PR1	positive vs. negative	0.018	0.005	3.0 [1.4-6.5]
Multivariate analysis with IPI, B symptoms, and S1PR1/pSTAT3 risk category
Clinicopathologic variables	Category	Univariate analysis	Multivariate analysis
		P ^*	P ^*	HR [95% CI]
IPI	3-5 vs. 0-2	0.009	0.021	2.7 [1.2-6.2]
B symptoms	present vs. absent	0.014	0.208	1.6 [0.7-3.9]
S1PR1/pSTAT3 risk category		0.010	0.019
	high risk (S1PR1+) vs. intermediate risk (S1PR1-/pSTAT3+)		0.024	2.7 [1.1-6.2]
	high risk (S1PR1+) vs. low risk (S1PR1-/pSTAT3-)		0.021	3.8 [1.2-11.6]

DLBCL, diffuse large B-cell lymphoma; IPI, international prognostic index. ^*P values less than 0.05 are considered significant.

ISSN: 1471-2407